Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, Division of Hematology/Oncology, speaks about the benefits of antibody drug conjugates (ADC) for multiple myeloma.
Raj Chakraborty: Benefits of Antibody Drug Conjugates for Multiple Myeloma
By Raj Chakraborty, MD - Last Updated: November 14, 2022Post Tags:MM
Related Posts
FDA shifts to real-time FAERS reporting, aiming to boost transparency in drug safety but raising concerns on data use.
While azacitidine plus venetoclax is a feasible treatment option, it did not improve patients outcomes.
In a narrative review Dr. Krina Patel participated in and describes in this interview, myeloma experts engaged this question.
Linvoseltamab drives deep, durable responses in relapsed/refractory multiple myeloma, even in high-risk patients.
Phase III MIDAS trial challenges ASCT’s role in MM, showing extended Isa-KRd may rival transplant in MRD-negative patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.